SGMO צמיחת הכנסות מרבעון לרבעון sangamo.com

Sangamo Therapeutics (SGMO) operates a business that is independent of economic fluctuations, as demand for the treatment of genetic pathologies remains stable. The relative change in quarterly revenue confirms this trend, with the 87.80 metric serving as the target level. Revenues currently rely on partner payments while testing continues. Patents for the ZFP platform provide the company with significant pricing power.
פילוחים אנליטיים ודוחות נתונים של חברת Sangamo (SGMO)

Quarterly revenue growth for Sangamo Therapeutics on the GURU.Markets platform reflects the effectiveness of the company's patent portfolio commercialization. This indicator measures the percentage change in sales volume between the current and previous quarters, capturing the speed of business scaling. The calculation model compares current receipts with historical data, identifying the impact of licensing agreements with pharma behemoths on cash flow. Stable dynamics confirm the fundamental resilience of the monetization model for scientific discoveries.